viewImmuPharma PLC

ImmuPharma’s chairman talks on widening of portfolio and focus on partnering opportunities

ImmuPharma PLC's (LON:IMM) Tim McCarthy caught up with Proactive London's Andrew Scott soon after the firm announced it had raised £1.5mln from a share subscription to fund an expansion of its research & development programmes.

The funding comprises a £200,000 share subscription by the company’s president and chief scientific officer Robert Zimmer as well as £1.3mln from Lanstead Capital - an institutional investor and significant shareholder in the business.

Its US partner, Avion Pharmaceuticals, is strengthening its advisory team for the phase III trial of its Lupuzor lupus treatment plus ImmuPharma's also planning a proof of concept study for Lupuzor in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

Quick facts: ImmuPharma PLC

Price: 12.625 GBX

Market: AIM
Market Cap: £31.09 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from...


ImmuPharma’s partner Avion set to meet FDA in December to discuss Phase 3...

Dr Tim Franklin, Chief Operating Officer of ImmuPharma PLC (LON:IMM) joins Proactive London's Katie Pilbeam to discuss ImmuPharma's announcement that The US Food & Drug Administration (“FDA”) has confirmed 4th December 2020 will be the date for the Type ‘A’ Meeting Request, with Avion...

3 days, 19 hours ago

2 min read